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such as the aorta, heart and brain as well as potentially deleterious
hyperhomocystinemia in PES-positive subjects (for references see
Slettedal et al., 2015). Such claims have independently been challenged
by data from other centers, which also has spoken against a clinically
signiﬁcant, true association between PES, vascular disease and, indirectly,
excess mortality (Tarkkanen, 2008; Anastasopoulos et al., 2015).
Although one tends to agree with the main conclusion of SlettedalAhundred years after its description in 1917by John Lindberg, a Finn-
an important message to millions of people — one has to address
potential bias in their statistics.0
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Fig. 1. Estimated conversion of subjects from pseudoexfoliation syndrome (PES)-negative to
positive status before the end of the study of Slettedal et al. (2015). The line graph is based on
the reported prevalence of PES by age group plotted at themidpoint of the age range and the
dashed arrows extend to the reported eventual median ages of the subjects for each age
group in their study. The prevalence of PES by the end of the follow-up for each age group
can be estimated from the plotted line graph as shown for the age group 65–69 years withish ophthalmologist (Tarkkanen and Kivelä, 2002) pseudoexfoliation
syndrome (PES) — an eye abnormality estimated to affect 80 million
people and to be associated with a signiﬁcantly increased risk of cataract
and secondary open-angle glaucoma, both of which may compromise
vision — continues to be shrouded in mysteries (Ritch, 2014;
Anastasopoulos et al., 2015). Why is PES so often unilateral? Why does
not everyone with PES develop secondary glaucoma? Why do lysyl
oxidase like-1 gene polymorphisms that are strongly associated with
PES (Thorleifsson et al., 2007) vary in different populations (Ji et al.,
2015)? What actually is the pseudoexfoliation material, visible in the
eye by biomicroscopy and elsewhere in the body by electronmicroscopy?
Is it identical inside and outside of the eye (Vesti and Kivelä, 2000)? Final-
ly, and perhaps most importantly, is PES a systemic disease that shortens
life expectancy? This is what Slettedal et al. (2015) from Norway, a
country with a long tradition of PES research, address in this issue of
EBioMedicine.
The authors conducted in 1985–1986 an epidemiological survey
covering 1888 of the 2109 inhabitants older than 64 years in three
Norwegian municipalities and determined by biomicroscopy whether
they were PES-positive (Ringvold et al., 1988). They returned to this
cohort in 2014 by which time 99% of their subjects had died, and
requested their dates of death (Slettedal et al., 2015). The authors
found no difference in all-cause mortality: the relative risk of death for
PES-positive subjects, adjusting for gender and age, was 1.01 and
the median life spans of PES-positive and PES-negative subjects were
similar in all age groups studied.
These long-term, population-based data corroborate half a dozen
cohort studies conducted previously albeit typically with shorter, less
mature follow-up — the Act 1 of addressing the potentially different
life spans of PES-positive subjects (for references see Slettedal et al.,
2015). As the authors point out, their results are also inconsistentom.2015.05.024.
pen access article under the CC BY-Net al. (2015) in that PES is unlikely to be a life threatening condition —
A notable confounding factor that the authors mention — and one
that they cannot adjust for— is that although several PES-negative sub-
jects most likely later converted to PES-positive ones they were still all
counted as PES-negative. One can roughly estimate the magnitude of
this bias as follows. First, the prevalence of PES by age group given in
Table 1 of Slettedal et al. (2015) can be plotted to provide prevalence
estimates for other ages (Fig. 1). Second, the eventual median age of
PES-negative subjects by age group can be read from Fig. 1 of Slettedal
et al. (2015). One can then read the corresponding predicted prevalence
of PES from the plot (Fig. 1) and calculate the number of PES-positivethe dotted bent arrow. Numbers on the left hand side of the dashed arrows are the PES-
positive subjects as reported in the study and those on the right hand side are the
corresponding estimates by the end of the study, obtained by multiplying the total number
of subjects in each age group by the estimated prevalence at the end of the study.
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
641T. Kivelä / EBioMedicine 2 (2015) 640–641subjects at the end of the study for each age group. For example, the
eventual median age for the 65–69 years old is 85 years, prevalence of
PES 28.5%, and number of PES-positive subjects 143 (as compared to
67 years, 11.0% and 55 at baseline— an increase of 88 subjects). Repeat-
ing this across all age groups returns a total number of 575 rather than
319 PES-positive subjects. If those who converted to PES-positive had
similar survival than thosewhowere PES-positive at baseline, themedi-
an life length of the PES-negative subjects would have been somewhat
higher, but not much; for example, the estimated median life span for
those 65–69 years old would be 4 months longer. This bias is unlikely
to change the main results.
However, another source of bias that the authors acknowledge,
namely analyzing only all-causemortality, cannot be dismissed as poten-
tially hiding clinically meaningful differences in cause-speciﬁc mortality.
PES has only been suspected of increasing cardio- and cerebrovascular
mortality (Anastasopoulos et al., 2015). It has not been implicated in
cancer, another major cause of death. Moreover, PES has often been
less common among diabetic patients (for references see Tarkkanen
et al., 2008). Because cardiovascular complications of diabetes shorten
survival, this diminishes chances of detecting any mortality excess
from PES. Luckily, this bias can still be addressed by Slettedal et al.
(2015), because causes of death are generally obtainable for valid re-
search purposes. There is, consequently, scope for Act 3 before excluding
shortened life spans in a subset of PES-positive subjects.
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